fabp10a Antibody

What is fabp10a and what is its biological function?

Fabp10a (Fatty Acid Binding Protein 10a, Liver Basic) is a cytoplasmic protein predominantly expressed in zebrafish liver. It functions primarily by binding hydrophobic ligands, particularly cholate, in the cytoplasm. Each fabp10a protein subunit has the capacity to bind one cholate molecule, suggesting an important role in bile acid transport and metabolism . This protein is believed to be involved in intracellular lipid transport mechanisms, though some of these functions are inferred by similarity to related proteins rather than through direct experimental evidence.

The temporal and spatial expression pattern of fabp10a is developmentally regulated. It is initially expressed in the developing embryonic liver starting from 48 hours post-fertilization (hpf) and continues to be expressed in the liver of 5-day-old zebrafish larvae. In adult zebrafish, fabp10a expression is primarily concentrated in the liver, with notably weaker expression detected in the testis and intestine . This tissue-specific expression pattern aligns with its proposed function in lipid metabolism and transport.

What are the key specifications of commercially available fabp10a antibodies?

Most commercially available fabp10a antibodies are rabbit polyclonal antibodies that recognize specific epitopes within the zebrafish (Danio rerio) fabp10a protein. These antibodies typically target defined regions of the protein, such as amino acids 30-63 at the N-terminal region . The antibodies have a calculated molecular weight recognition of approximately 14004 Da, which corresponds to the molecular weight of the fabp10a protein.

The purification process for these antibodies typically involves a two-step procedure: initial purification through a protein A column followed by peptide affinity purification to enhance specificity . This rigorous purification process helps minimize cross-reactivity with other proteins. The antibodies are commonly supplied in a phosphate-buffered saline (PBS) solution containing 0.09% sodium azide as a preservative. Most fabp10a antibodies are validated for Western blotting applications with a recommended dilution of 1:1000 .

How does fabp10a differ from other FABP family members?

Fabp10a belongs to the fatty acid binding protein family but possesses distinct structural and functional characteristics. Unlike some other FABP family members, fabp10a is also known as liver basic FABP (L-BABP) or liver-type FABP (L-FABP) due to its predominant expression in liver tissue . The protein features a PFAM domain that differs from related family members like FABP9, which possesses a lipocalin domain, while FABP10 contains a peptidase_C41 domain according to SMART software analysis .

In immunological contexts, fabp10a shows distinctive bacterial binding patterns compared to other FABP family members. Research indicates that while both FABP9 and FABP10 can bind to Gram-positive and Gram-negative bacteria, they demonstrate different binding affinities and specificities . This suggests that despite sharing the FABP family designation, these proteins likely serve specialized functions in different physiological contexts. The tissue distribution pattern of fabp10a also differs from other FABPs, with its strong liver specificity contrasting with the broader distribution patterns seen in some other family members.

How should I optimize Western blotting protocols when using fabp10a antibodies?

When utilizing fabp10a antibodies for Western blotting, several optimization steps are crucial for obtaining clean and specific results. Begin with sample preparation using an appropriate lysis buffer that contains protease inhibitors to prevent protein degradation during extraction from zebrafish tissues. Given that fabp10a is primarily expressed in liver tissue, ensure proper homogenization of liver samples for optimal protein extraction .

For the electrophoresis step, 12-15% SDS-PAGE gels are recommended due to the relatively low molecular weight (14004 Da) of the fabp10a protein . Transfer the proteins to a PVDF or nitrocellulose membrane using standard transfer parameters, but consider optimizing transfer time for small proteins to prevent them from passing through the membrane. During the blocking step, use 5% non-fat dry milk or BSA in TBST for 1-2 hours at room temperature. The primary antibody incubation should follow the manufacturer's recommended dilution, typically 1:1000 for fabp10a antibodies . For optimal results, incubate overnight at 4°C with gentle agitation. After washing with TBST, apply an appropriate HRP-conjugated secondary antibody against rabbit IgG and develop using either enhanced chemiluminescence or fluorescence-based detection systems.

What are effective approaches for validating fabp10a antibody specificity?

Validating the specificity of fabp10a antibodies is essential for ensuring reliable experimental results. One effective validation approach is to perform comparative Western blot analysis using tissues with known differential expression of fabp10a. Since fabp10a is predominantly expressed in liver tissue with minimal expression in intestine and testis, these tissues can serve as positive and negative controls respectively . A specific antibody should show strong signal in liver samples and weak or absent signal in non-expressing tissues.

Another robust validation method is to use recombinant fabp10a protein as a positive control. Prepare a dose-response curve with different concentrations of purified recombinant protein to confirm antibody sensitivity and linearity of detection. Additionally, pre-absorption tests can be performed by incubating the antibody with excess immunizing peptide before application to Western blots or other assays. A significant reduction in signal after pre-absorption indicates antibody specificity for the target epitope. For more rigorous validation, consider using zebrafish fabp10a knockdown or knockout models, where specific reduction or absence of signal would confirm antibody specificity . Finally, comparing results from multiple antibodies targeting different epitopes of fabp10a can provide additional confirmation of specificity.

What tissue collection and preparation methods are optimal for fabp10a immunodetection?

For optimal fabp10a immunodetection in zebrafish tissues, proper sample collection and preservation are critical. Since fabp10a is predominantly expressed in liver tissue, with development-dependent expression patterns, consider the age of the specimens when collecting samples. For embryonic studies, collect samples after 48 hpf when fabp10a expression begins in the developing liver . For adult zebrafish, surgical extraction of liver tissue should be performed quickly following euthanasia to minimize protein degradation.

Immediately after collection, tissues should be flash-frozen in liquid nitrogen and stored at -80°C until processing, or fixed in an appropriate fixative for immunohistochemistry. For protein extraction, homogenize tissue samples in a lysis buffer containing protease inhibitors (e.g., PMSF, aprotinin, leupeptin) using mechanical disruption methods such as sonication or homogenization. Centrifuge the homogenate at 10,000-15,000 × g for 15-20 minutes at 4°C to remove cellular debris. Determine protein concentration using Bradford or BCA assays before proceeding with Western blotting or other applications. For immunohistochemical applications, fix tissues in 4% paraformaldehyde, embed in paraffin or optimal cutting temperature (OCT) compound, and section at 5-10 μm thickness for optimal antibody penetration and signal detection.

Why might I see non-specific binding when using fabp10a antibodies, and how can I minimize it?

Non-specific binding is a common challenge when working with antibodies, including those targeting fabp10a. Several factors may contribute to this issue, including insufficient blocking, high antibody concentration, or cross-reactivity with structurally similar proteins from the FABP family. The high sequence similarity between different FABP family members can lead to antibody cross-reactivity, particularly when using polyclonal antibodies . Additionally, using too high an antibody concentration can increase background signal and non-specific binding.

To minimize non-specific binding, implement these optimizations: First, increase the blocking step duration using 5% non-fat dry milk or BSA in TBST for at least 2 hours at room temperature. Second, optimize antibody dilution through a titration series, testing dilutions ranging from 1:500 to 1:5000 to identify the concentration that provides specific signal with minimal background. Third, increase washing stringency by extending wash times and adding a small amount (0.1-0.2%) of additional detergent like Tween-20 or Triton X-100 to the wash buffer. Fourth, consider pre-absorbing the antibody with acetone powder prepared from tissues not expressing fabp10a to remove antibodies that might recognize common epitopes. Finally, include appropriate negative controls in each experiment, such as samples from tissues known not to express fabp10a, to help identify non-specific binding patterns .

How can I determine if my fabp10a antibody has lost activity during storage?

Antibody activity can diminish over time due to improper storage conditions or repeated freeze-thaw cycles. To assess whether your fabp10a antibody has maintained its activity, perform a comparative Western blot analysis using a previously tested positive control sample alongside your current experiment. A significant reduction in signal intensity compared to historical results suggests potential loss of antibody activity.

Implement a positive control testing protocol by creating aliquots of standardized zebrafish liver lysate or recombinant fabp10a protein at known concentrations. Store these aliquots at -80°C and use a fresh aliquot each time you test a new or stored antibody preparation. Record the signal intensity for each test to create a reference standard. Additionally, monitor the appearance of non-specific bands, which may increase as antibody quality deteriorates. If you suspect activity loss, perform a titration series with increasing antibody concentrations to determine if higher concentrations can compensate for reduced activity. To prevent future activity loss, store antibodies in small working aliquots at -20°C to -80°C, avoid repeated freeze-thaw cycles, and consider adding carrier proteins like BSA (0.1-1%) if not already present in the antibody solution .

What strategies can address weak signal issues when detecting fabp10a?

Weak signal detection when working with fabp10a antibodies can result from multiple factors including low target protein abundance, insufficient antibody sensitivity, or suboptimal detection methods. To address these challenges, first ensure you are working with appropriate tissue samples, as fabp10a is primarily expressed in the liver with developmental timing considerations (expression begins at 48 hpf in zebrafish embryos) . Using tissues with low expression levels may naturally result in weak signals.

To enhance signal detection, consider these approaches: First, optimize protein extraction by using more efficient lysis buffers containing mild detergents like NP-40 or Triton X-100, and ensure complete tissue disruption. Second, increase the protein loading amount on Western blots, but be cautious about overloading, which can cause smearing. Third, extend the primary antibody incubation time to overnight at 4°C, or even up to 48 hours for particularly weak signals. Fourth, switch to more sensitive detection systems such as enhanced chemiluminescence (ECL) plus or super signal reagents, which can provide 10-50 times more sensitivity than standard ECL. Fifth, use signal amplification methods such as biotin-streptavidin systems or tyramide signal amplification for immunohistochemistry applications. Finally, consider concentrating your protein samples using methods such as TCA precipitation or acetone precipitation if the target protein concentration is particularly low .

How can fabp10a antibodies be effectively utilized in immunoprecipitation experiments?

Immunoprecipitation (IP) with fabp10a antibodies can be valuable for studying protein-protein interactions and post-translational modifications. When designing fabp10a IP experiments, begin by selecting an antibody that binds to a region of the protein that is not involved in potential protein-protein interactions to avoid disrupting these associations. Since fabp10a is known to bind hydrophobic ligands and may be involved in intracellular transport , careful antibody selection is particularly important.

For effective fabp10a immunoprecipitation, prepare cell or tissue lysates in non-denaturing buffer conditions to preserve protein-protein interactions. A typical buffer might contain 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40 or 0.5% Triton X-100, and protease inhibitors. Pre-clear the lysate with Protein A/G beads to reduce non-specific binding. Incubate the pre-cleared lysate with fabp10a antibody overnight at 4°C using 2-5 μg of antibody per 500 μg of total protein. Add fresh Protein A/G beads and incubate for an additional 2-4 hours, then wash extensively with IP buffer to remove unbound proteins. For co-immunoprecipitation studies, perform Western blot analysis on the immunoprecipitated material using antibodies against potential interacting partners. Given fabp10a's role in lipid transport, consider investigating interactions with membrane proteins or other lipid binding proteins. Control experiments using non-specific IgG from the same species as the fabp10a antibody are essential to identify non-specific binding .

What approaches can be used to study fabp10a expression changes during developmental processes?

Studying fabp10a expression changes during zebrafish development requires combining multiple methodological approaches. Temporal expression patterns can be analyzed using stage-specific qRT-PCR to quantify mRNA levels from various developmental timepoints, particularly focusing on stages around 48 hpf when expression begins in the embryonic liver . This should be complemented with Western blot analysis using fabp10a antibodies to determine if protein expression correlates with mRNA levels or exhibits post-transcriptional regulation.

For spatial expression analysis, whole-mount immunohistochemistry using fabp10a antibodies on fixed zebrafish embryos can visualize the tissue-specific localization of the protein. This can be enhanced with confocal microscopy to provide detailed 3D distribution patterns. Alternatively, immunohistochemistry on tissue sections from different developmental stages offers higher resolution of expression patterns within specific organs. For functional studies, morpholino-mediated knockdown or CRISPR/Cas9-generated mutants of fabp10a can reveal the developmental consequences of reduced protein expression. To investigate regulatory mechanisms, reporter assays using the fabp10a promoter region driving a fluorescent protein can identify cis-regulatory elements controlling developmental expression. Time-lapse imaging of such reporter lines can provide dynamic information about expression changes. These approaches can be further enhanced by examining fabp10a expression under various experimental conditions, such as exposure to different lipids or bile acids, to understand the functional significance of expression changes .

How can fabp10a antibodies contribute to studies on liver diseases in zebrafish models?

Fabp10a antibodies offer valuable tools for investigating liver diseases in zebrafish models due to the protein's liver-specific expression pattern. In zebrafish steatosis models, created through high-fat diets or chemical inducers, immunohistochemistry with fabp10a antibodies can serve as a hepatocyte marker to assess morphological changes and patterns of lipid accumulation. Changes in fabp10a expression levels, detected via Western blotting, may correlate with disease progression or severity, potentially serving as a biomarker for hepatic stress or damage.

For inflammatory liver disease models, dual immunofluorescence staining with fabp10a antibodies and markers for inflammatory cells can reveal the spatial relationship between hepatocytes and immune cell infiltration. This approach can help characterize the inflammatory microenvironment during disease progression. In zebrafish liver regeneration studies, following partial hepatectomy or chemical-induced liver damage, fabp10a immunostaining can track hepatocyte regeneration and organization during the recovery process. For toxicological studies, fabp10a antibodies can help assess hepatocyte responses to various toxicants, with potential changes in fabp10a expression or localization serving as indicators of hepatocellular stress or adaptive responses. Additionally, in genetic models of liver disease, fabp10a antibodies can help characterize phenotypic changes in hepatocyte morphology, organization, or function. These applications make fabp10a antibodies particularly valuable for comparative studies between zebrafish liver disease models and human hepatic pathologies .

How should I analyze and interpret unexpected fabp10a expression patterns in experimental results?

When encountering unexpected fabp10a expression patterns, a systematic approach to data interpretation is essential. First, verify the technical validity of your findings by repeating the experiment with appropriate controls, including positive controls (known fabp10a-expressing tissues like adult zebrafish liver) and negative controls (tissues without fabp10a expression) . If the unexpected patterns persist, consider whether experimental conditions might have altered fabp10a expression. Research has shown that challenge with immunostimulants like LPS can alter FABP expression patterns in immune tissues , suggesting that fabp10a might respond to specific physiological or pathological stimuli.

Investigate potential regulatory mechanisms by examining whether transcriptional or post-transcriptional processes might explain the unexpected expression patterns. This could involve comparing mRNA levels (via qRT-PCR) with protein levels (via Western blotting) to identify potential discrepancies suggesting post-transcriptional regulation. Consider the possibility of detecting fabp10a splice variants or closely related FABP family members if the antibody exhibits any cross-reactivity . Developmental timing may also play a role, as fabp10a expression begins at specific developmental stages (48 hpf in zebrafish embryos) . Finally, unexpected expression patterns might represent genuine novel findings about fabp10a biology. In such cases, follow-up experiments using complementary techniques such as in situ hybridization, reporter gene assays, or functional studies with gene knockdown/knockout approaches can help validate and expand upon these unexpected observations.

How can I quantitatively compare fabp10a expression levels between different experimental conditions?

Quantitative comparison of fabp10a expression across experimental conditions requires rigorous standardization and appropriate statistical analysis. For Western blot quantification, use densitometry software (e.g., ImageJ, Image Studio Lite) to measure band intensities of both fabp10a and a loading control such as β-actin or GAPDH. Calculate the relative expression by normalizing fabp10a band intensity to the loading control for each sample. This normalization compensates for variations in total protein loading between samples.

For more precise quantification, consider employing an enzyme-linked immunosorbent assay (ELISA) using fabp10a antibodies. This approach allows direct measurement of protein concentration against a standard curve generated with recombinant fabp10a protein. Alternatively, quantitative immunohistochemistry can be performed by standardizing all staining parameters (antibody concentrations, incubation times, development conditions) and using image analysis software to measure staining intensity across experimental groups. For all quantitative approaches, biological replicates (n≥3) are essential, and technical replicates help minimize measurement variability. Apply appropriate statistical tests such as t-tests for comparing two conditions or ANOVA for multiple conditions, followed by post-hoc tests as needed. Report results with measures of central tendency (mean or median) and dispersion (standard deviation or standard error), along with precise p-values. Additionally, consider reporting effect sizes to indicate the magnitude of differences between experimental conditions .

What considerations are important when comparing results from different fabp10a antibodies?

When comparing results obtained using different fabp10a antibodies, several critical factors must be considered to ensure valid interpretations. First, examine the epitope specificity of each antibody, as antibodies targeting different regions of the fabp10a protein may yield different results. For instance, antibodies targeting the N-terminal region (amino acids 30-63) versus the central region may have different accessibility to the epitope depending on protein folding or interactions with other molecules .

Second, compare the technical specifications of the antibodies, including host species, clonality (polyclonal vs. monoclonal), and purification methods. Polyclonal antibodies may recognize multiple epitopes, potentially offering higher sensitivity but lower specificity compared to monoclonal antibodies. Third, standardize experimental conditions when possible, including sample preparation, protein extraction methods, antibody dilutions (adjusted for relative affinities), and detection systems. Fourth, perform validation experiments for each antibody using positive and negative controls to establish specificity and sensitivity profiles. This might include Western blots of recombinant fabp10a protein and tissue samples with known expression patterns. Finally, when reporting results from multiple antibodies, clearly document the specific antibody used for each experiment, including catalog numbers and lot numbers when possible, as lot-to-lot variations can occur. If inconsistencies between antibodies persist despite these controls, consider the possibility that they might be detecting different conformational states, splice variants, or post-translationally modified forms of fabp10a .